# UroGen Pharma Ltd. (URGN) FY2026 Q2 Balance Sheet

- Company: UroGen Pharma Ltd. (URGN)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001437749-26-025794
- Page: https://plicit.ai/financials/urgn/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/urgn-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 252,590,000 US dollars
- **Current assets**: 235,426,000 US dollars
- **Non-current assets**: 17,164,000 US dollars
- **Liabilities**: 384,986,000 US dollars
- **Current liabilities**: 61,915,000 US dollars
- **Non-current liabilities**: 323,071,000 US dollars
- **Equity**: negative 132,396,000 US dollars
- **Accounts receivable, net**: 88,757,000 US dollars
- **Cash and cash equivalents**: 79,133,000 US dollars
- **Marketable securities**: 28,842,000 US dollars
- **Inventories**: 24,589,000 US dollars
- **Prepaid expenses and other current assets**: 12,776,000 US dollars
- **Restricted cash**: 1,329,000 US dollars
- **Other non-current assets**: 8,761,000 US dollars
- **Finance lease right-of-use assets**: 4,818,000 US dollars
- **Operating lease right-of-use assets**: 2,810,000 US dollars
- **Property and equipment, net**: 597,000 US dollars
- **Restricted deposit**: 178,000 US dollars
- **Accounts payable and accrued expenses**: 39,945,000 US dollars
- **Employee related accrued expenses**: 12,253,000 US dollars
- **Other current liabilities**: 7,622,000 US dollars
- **Current liabilities related to finance leases**: 1,411,000 US dollars
- **Current liabilities related to operating leases**: 684,000 US dollars
- **Long-term debt**: 188,734,000 US dollars
- **Prepaid forward obligation**: 125,135,000 US dollars
- **Uncertain tax positions liability**: 3,903,000 US dollars
- **Finance long-term lease liabilities**: 2,939,000 US dollars
- **Operating long-term lease liabilities**: 2,360,000 US dollars
- **Additional paid-in capital**: 865,112,000 US dollars
- **Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at June 30, 2026 and December 31, 2025; 48,869,530 and 48,350,272 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively**: 135,000 US dollars
- **Accumulated deficit**: negative 997,641,000 US dollars
- **Accumulated other comprehensive income**: negative 2,000 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.